FindTrial
Sign In

Survey on treatment pattern of Mature B cell neoplasms (MBCN) patients in China.

Survey on treatment pattern of Mature B cell neoplasms (MBCN) patients in China.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075211
Enrollment
Unknown
Registered
2023-08-29
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mature B cell neoplasms

Interventions

qualitative survey:NA
Quantitative survey:NA

Sponsors

Hematology Hospital of the Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: KOL recruiting criteria: • Authors of guidelines and consensus in the field of hematology in recent 3 years • Members of academic associations, such as CMA or CSCO in recent 3 years • Speakers of domestic or global hematology associated conference, such as CSH, ASH, or EHA in recent 3 years • Provide informed consent Physician recruiting criteria: • =5 years of experience in managing patients with MBCN • Treats =15 patients with MBCN each year • Have prescribed BTKis in the past 1 year • Provide informed consent

Exclusion criteria

Exclusion criteria: Not applicable.

Design outcomes

Primary

MeasureTime frame
clinical treatment patterns of Chinese MBCN patients;—

Secondary

MeasureTime frame
understand the patient-related, disease-related, and treatment-related unmet needs of BTKis and ADCs.;—

Countries

China

Contacts

Public ContactQiu Lugui

Hematology Hospital of the Chinese Academy of Medical Sciences

qiulg@ihcams.ac.cn+86 22 2390 9999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026